September 2, 2024
Emyria (ASX:EMD) reports promising interim results in MDMA-assisted therapy for PTSD
Emyria has reported substantial improvements in PTSD symptoms and quality of life among patients in its MDMA-assisted therapy program, underscoring the treatment’s potential to address significant unmet needs in mental health care.